Atrovastain

Phase 2Small molecule

AAssiut University

Atrovastain is one of 18 small molecule programs targeting Cardiotoxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiotoxicityNot yet recruiting

CardiotoxicityPhase 2

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Cardiotoxicity

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

1 2

Coreg

Akero Therapeutics

Approved

4 3

Avelox

Jardiance

2 5

Farxiga

AstraZeneca

Phase 2

5 6

Adriamycin

Pfizer

Phase 2

3 7

Micardis

Boehringer Ingelheim

Phase 2

1 8

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 9

Corlanor

Amgen

Preclinical

2 10

Atacand

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1/2Not yet recruiting

Cardiotoxicity

NCT06684509

Clinical

Trials by Indication[1]

Cardiotoxicity1 trial

Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia

Not yet recruiting·—·Phase 1/2·NCT06684509·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atrovastain. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atrovastain compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atrovastain. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssiut University

Atrovastain

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Cardiotoxicity1 trial

References

Drug Info

Quick Facts

Related News